Pemetrexed plus Cisplatin Safe, Effective for Advanced Urothelial Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the British Journal of Cancer, the combination of pemetrexed and cisplatin shows activity and is well tolerated for the treatment of patients with advanced urothelial carcinoma.

For the phase 2 study, researchers sought to evaluate the efficacy and safety of pemetrexed, which has previously demonstrated a 30% response rate with minimal toxicity when used as monotherapy for advanced urothelial carcinoma, plus cisplatin for the treatment of patients with advanced urothelial carcinoma.

In the single-arm, multicenter, open-label study, researchers enrolled 42 patients with advanced urothelial carcinoma. Patients had a median age of 66 years and an ECOG performance score of 0-1. Of those enrolled, about 55% had visceral metastases and 57.1% had recurrent disease. All patients received pemetrexed 500mg/m2 intravenously plus cisplatin 70mg/m2 intravenously on day 1 every 3 weeks.

Results showed 27 partial responses, which corresponds to an overall response rate of 64.3% (95% CI: 49.2 - 77.0).

In addition, seven patients had stable disease. The median progression-free survival was 6.9 months (95% CI: 6.2 - 7.6) and the median overall survival was 14.4 months (95% CI: 10.4 - 18.4). In regard to safety, 28.6% of patients experienced grade 3 or 4 neutropenia, but no patients had febrile neutropenia.

For Patients With Bladder Cancer, Inadequate Biopsies May Increase 5-Year Mortality
Pemetrexed and cisplatin shows activity for the treatment of patients with advanced urothelial carcinoma.
This phase II study evaluated the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma. The combination of pemetrexed and cisplatin is active, and well tolerated in patients with advanced urothelial cancer as a first-line treatment.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs